Phase I/II Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor PD-0325901 for Patients With KRAS Mutant Non-Small Cell Lung Cancer and Other Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Mirdametinib (Primary) ; Palbociclib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 08 Oct 2019 Planned primary completion date changed from 30 Nov 2019 to 31 Dec 2019.
- 09 Apr 2019 Planned primary completion date changed from 30 Nov 2018 to 30 Nov 2019.
- 10 Oct 2018 Planned primary completion date changed from 31 Aug 2018 to 30 Nov 2018.